ALDH1A1 (Aldehyde Dehydrogenase 1 Family, Member A1) is a NAD+-dependent enzyme that catalyzes the oxidation of aldehydes to carboxylic acids [1]. In the brain, ALDH1A1 plays critical roles in detoxifying reactive aldehydes generated during neurotransmitter metabolism, particularly the aldehydes produced from dopamine oxidation [2]. This enzyme is highly expressed in dopaminergic neurons of the substantia nigra pars compacta and serves as a key protective mechanism against aldehyde-induced neurotoxicity [3].
bfe67bb53c3c532ef4237fa3323691ae27404769
ALDH1A1 is a homotetrameric enzyme with each subunit containing:
- NAD-binding Domain: Binds NAD+ cofactor in a Rossmann fold structure [4]
- Catalytic Domain: Contains the active site with a catalytic cysteine (Cys302) [4]
- Substrate-binding Pocket: Accommodates various aldehyde substrates including retinaldehydes and dopamine-derived aldehydes [5]
- Oligomerization Interface: Mediates tetramer formation essential for enzyme activity [4]
ALDH1A1 catalyzes the oxidation of retinaldehyde (vitamin A aldehyde) to retinoic acid, the active form of vitamin A [6]:
- Retinoic acid is a crucial morphogen in embryonic development
- In the adult brain, retinoic acid regulates synaptic plasticity and neurogenesis [7]
- Retinoic acid signaling is implicated in dopaminergic neuron maintenance [8]
Following dopamine oxidation, ALDH1A1 detoxifies the resulting aldehydes:
- Dopamine Oxidation: MAO-B catalyzes oxidative deamination of dopamine → 3,4-dihydroxyphenylacetaldehyde (DOPAL) [2]
- Aldehyde Detoxification: ALDH1A1 oxidizes DOPAL to 3,4-dihydroxyphenylacetic acid (DOPAC) [2]
- Prevention of Toxic Accumulation: DOPAL is neurotoxic; ALDH1A1 prevents its accumulation [9]
- 4-Hydroxy-2-nonenal (4-HNE) - lipid peroxidation product
- Acetaldehyde - ethanol metabolite
- Formaldehyde - endogenous aldehyde
- Various aromatic and aliphatic aldehydes [10]
ALDH1A1 vulnerability is a hallmark of Parkinson's disease:
- Selective Loss: ALDH1A1+ dopaminergic neurons in substantia nigra are particularly vulnerable in PD [3]
- Reduced ALDH1A1 Expression: Decreased ALDH1A1 mRNA and protein in PD substantia nigra [11]
- DOPAL Accumulation: Impaired aldehyde detoxification leads to DOPAL accumulation [9]
- Mechanisms: DOPAL promotes alpha-synuclein aggregation, mitochondrial dysfunction, and neuronal death [12]
ALDH1A1 dysregulation is implicated in AD:
- Retinoic Acid Signaling Impairment: Reduced ALDH1A1 decreases retinoic acid synthesis [13]
- Oxidative Stress: 4-HNE detoxification is impaired, increasing oxidative damage [14]
- Amyloid Pathology: Retinoic acid deficiency may affect amyloid processing [15]
- ALDH1A1 activity declines with age in the substantia nigra [16]
- This age-related decline may increase susceptibility to dopaminergic neurodegeneration
- ALDH1A1 Activators: Small molecules that enhance ALDH1A1 activity
- Gene Therapy: AAV-mediated ALDH1A1 overexpression [17]
- Substrate Analogs: Compounds that enhance DOPAL detoxification
- ALDH1A1 expression in peripheral blood cells as a PD biomarker [18]
- ALDH1A1 polymorphisms associated with PD risk [19]
- Retinoic acid supplementation to compensate for reduced ALDH1A1
- Antioxidant therapy to reduce aldehyde formation
- MAO-B inhibitors indirectly reduce DOPAL load [20]
Additional evidence sources: